We claim:

1. A compound of formula I



I

in which

R^1 is methyl, ethyl, propyl, or butyl;

R^2 is H, OH, NH_2, or NH-(C_1-C_6)-alkyl;

R^3 is a sugar radical, a disugar radical, a trisugar radical, a tetrasugar radical, wherein said radicals are optionally mono- or polysubstituted by a sugar protective group;

R^4 is methyl, ethyl, propyl, or butyl;

R^5 is methyl, ethyl, propyl, or butyl;

Z is $-(C=O)_n-(C_0-C_{16})$-alkyl, $-(C=O)_n-(C_0-C_{16})$-alkyl-NH-, $-(C=O)_n-(C_0-C_{16})$-alkyl-O-, $-(C=O)_n-(C_1-C_{16})$-alkyl-$(C=O)_m$, or a covalent bond;

n is 0 or 1;

m is 0 or 1;

or a pharmaceutically tolerable salt thereof, or a physiologically functional derivative thereof.

2. The compound of formula I as claimed in claim 1, wherein:

R^1 is ethyl, propyl, or butyl;

R^2 is H, OH, NH_2, or NH-(C_1-C_6)-alkyl;

R^3 is a sugar radical or disugar radical, wherein said radicals are optionally mono- or polysubstituted by a sugar protective group;

R^4 is methyl, ethyl, propyl, or butyl;

R^5 is methyl, ethyl, propyl, or butyl;

Z is -(C=O)$_n$-(C_0-C_{16})-alkyl-, -(C=O)$_n$-(C_0-C_{16})-alkyl-NH-, -(C=O)$_n$-(C_0-C_{16})-alkyl-O-, -(C=O)$_n$-(C_1-C_{16})-alkyl-(C=O)$_m$, or a covalent bond;

n is 0 or 1;

m is 0 or 1;

or a pharmaceutically tolerable salt thereof.

3. The compound of formula I as claimed in claim 1, wherein:

R^1 is ethyl or butyl;

R^2 is OH;

R^3 is a sugar radical, wherein the sugar radical is optionally mono- or polysubstituted by a sugar protective group;

R^4 is methyl;

R^5 is methyl;

Z is -(C=O)-(C_0-C_4)-alkyl or a covalent bond;

or a pharmaceutically tolerable salt thereof.

4. A compound of the following structure:



or a pharmaceutically tolerable salt thereof.

5. A pharmaceutical composition, comprising the compound as claimed in claim 4, and at least one pharmacologically tolerable excipient.

6. A method for the prophylaxis or treatment of a lipid metabolism disorder in a human or animal patient, comprising:
administering to the patient in need of said prophylaxis or treatment an effective amount of the compound as claimed in claim 4.

7. A method for the prophylaxis or treatment of gallstones in a human or animal patient, comprising:
administering to the patient in need of such prophylaxis or treatment an effective amount of the compound as claimed in claim 4.

8. A method for the prophylaxis or treatment of hyperlipidemia in a human or animal patient, comprising:
administering to the patient in need of such prophylaxis or treatment an effective amount of the compound as claimed in claim 4.

9. A method for lowering the serum cholesterol level in a human or animal patient, comprising:
administering to the patient in need of said lowering an effective amount of the compound as claimed in claim 4.

10. A method for the prophylaxis or treatment of one or more arteriosclerotic symptoms in a human or animal patient, comprising:
administering to the patient in need of said prophylaxis or treatment an effective amount of the compound as claimed in claim 4.

11. A compound of the following structure:



or a pharmaceutically tolerable salt thereof.

12. A pharmaceutical composition, comprising the compound as claimed in claim 11, and at least one pharmacologically tolerable excipient.

13. A method for the prophylaxis or treatment of a lipid metabolism disorder in a human or animal patient, comprising:
administering to the patient in need of said prophylaxis or treatment an effective amount of the compound as claimed in claim 11.

14. A method for the prophylaxis or treatment of gallstones in a human or animal patient, comprising:
administering to the patient in need of such prophylaxis or treatment an effective amount of the compound as claimed in claim 11.

15. A method for the prophylaxis or treatment of hyperlipidemia in a human or animal patient, comprising:
administering to the patient in need of such prophylaxis or treatment an effective amount of the compound as claimed in claim 11.

16. A method for lowering the serum cholesterol level in a human or animal patient, comprising:
administering to the patient in need of said lowering an effective amount of the compound as claimed in claim 11.

17. A method for the prophylaxis or treatment of one or more arteriosclerotic symptoms in a human or animal patient, comprising:
administering to the patient in need of said prophylaxis or treatment an effective amount of the compound as claimed in claim 11.

18. A process for the preparation of a compound of formula I, as claimed in claim 1, wherein said process comprises reacting, according to the following equation,



an amine of formula II or a salt thereof, in which R^1, R^2, R^4 and R^5 have the meanings indicated for formula I, with a compound of formula III or a salt thereof, in which R^3 and Z have the meanings indicated for formula I, with elimination of water to give a compound of formula I; and optionally converting the compound of formula I obtained into a physiologically tolerable salt thereof.

19. A pharmaceutical composition comprising one or more compounds of formula I as claimed in claim 1, and at least one pharmacologically tolerable excipient.

20. The pharmaceutical composition as claimed in claim 19, further comprising one or more statins.

21. A pharmaceutical composition for the prophylaxis or treatment of a lipid metabolism disorder, comprising an effective amount of one or more compounds of formula I as claimed in claim 1, and at least one pharmacologically tolerable excipient.

22. A method for the prophylaxis or treatment of a lipid metabolism disorder in a human or animal patient, comprising:
administering to the patient in need of said prophylaxis or treatment an effective amount of the compound of formula I as claimed in claim 1.

23. A pharmaceutical composition for the prophylaxis or treatment of gallstones, comprising an effective amount of one or more compounds of formula I as claimed in claim 1, and at least one pharmacologically tolerable excipient.

24. A method for the prophylaxis or treatment of gallstones in a human or animal patient, comprising:
administering to the patient in need of such prophylaxis or treatment an effective amount of the compound of formula I as claimed in claim 1.

25. A pharmaceutical composition for the prophylaxis or treatment of hyperlipidemia, comprising an effective amount of one or more compounds of formula I as claimed in claim 1, and at least one pharmacologically tolerable excipient.

26. A method for the prophylaxis or treatment of hyperlipidemia in a human or animal patient, comprising:
administering to the patient in need of such prophylaxis or treatment an effective amount of the compound of formula I as claimed in claim 1.

27. A pharmaceutical composition for lowering the serum cholesterol level in a human or animal patient, comprising an effective amount of one or more compounds of formula I as claimed in claim 1, and at least one pharmacologically tolerable excipient.

28. A method for lowering the serum cholesterol level in a human or animal patient, comprising:
administering to the patient in need of said lowering an effective amount of the compound of formula I as claimed in claim 1.

29. A pharmaceutical composition for the prophylaxis or treatment of one or more arteriosclerotic symptoms, comprising an effective amount of one or more

compounds of formula I as claimed in claim 1, and at least one pharmacologically tolerable excipient.

30. A method for the prophylaxis or treatment of one or more arteriosclerotic symptoms in a human or animal patient, comprising:
administering to the patient in need of said prophylaxis or treatment an effective amount of the compound of formula I as claimed in claim 1.